Date:5/13/2010

-------------- 13,762 19,553 ------------------------------------------------------------------------- Loss from operations (7,340) (13,442) ------------------------------------------------------------------------- Other income Interest income 58 154 Foreign exchange gain 1,402 900 ------------------------------------------------------------------------- 1,460 1,054 ------------------------------------------------------------------------- Net loss for the period (5,880) (12,388) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Net loss per share Basic and diluted (0.09) (0.23) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Weighted average number of shares Basic and diluted 63,089,954 53,187,470 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Interim Consolidated Balance Sheet Information (in thousands) (unaudited) ------------------------------------------------------------------------- As at As at March 31, December 31, 2010 2009 ------------------------------------------------------------------------- ----------------------------
'/>"/>

SOURCE AETERNA ZENTARIS INC. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share